Jiangsu Bioperfectus Technologies Co., Ltd.

In December 2021, the world faced a new outbreak with the COVID-19 Omicron variant,which triggered another chapter in the COVID-19 pandemic. The highly transmissible Omicron variant of COVID-19 has been driving an unprecedented surge of infections globally. With the rise of the omicron variant, the ability of diagnostic tests to detect the Omicron variant was critical to tracking its spread and putting measures to halt transmission in place.PCR tests are accurate but can take a long time to produce results. Antigen tests, the other primary type of coronavirus test, offer the advantage of producing results much more quickly. Antigen tests are quick and easy diagnostic tests to identify patients infected with SARS-CoV-2.The Israeli ministry of health aimed to make antigen rapid tests available as a screening tool for Israeli citizens, reduce community transmission, and keep the economy running. The Israeli ministry of health urgently needed to find potential IVD suppliers to offer antigen rapid test kits that meet high quality and global regulatory standards. Earlyin the omicron surge,many manufacturers' antigen rapid test kits had a limited ability to detectOmicroninfections, and rapid antigen testsmay be spitting out false positives. Based on the excellent cooperation and trust between Bioperfectus and the Israeli distributor, Bioperfectus received an urgent request from the distributor to participate in a tender for Novel Corona Virus antigen rapid test kits. As required by the Israeli ministry of health, the supplier must provide sufficient clinical evidence on the antigen rapid test kit and assist the Israeli ministry of health in conducting the clinical evaluation, which ensures that test kits can detect the Omicron virus accurately. Through a critical assessment of clinical evaluation and data validation, Bioperfectus successfully passed the Israeli ministry of health inspection. Bioperfectus was the only Chinese company on the procurement list and was asked to provide two million antigen rapid test kits for the Israeli ministry of health. The Bioperfectus production department immediately deployed a team to take charge of this task, given the highest priority andurgency, working closely with the supply chain and warehouse management team, from raw material procurement to production and packaging. With Lunar New Yearapproaching, the production department organized the plan and kept production running smoothly and effectively. At the same time, the international business team coordinated and supported different departments to ensure supplies were delivered on time. Another challenge Bioperfectus faced was the issue of international logistics. The major international airlines were disrupted due to the spread of the omicron variant. The international business team created a flexible solution to deliver two million test kits to Israel in three batches within the deadline. It's a race against time. Greatteams worktogether toaccomplishthe great result. The team leader of the international business department said. More critical for Bioperfectus is to support the Israeli authorities in response to the Omicron variant and protect local people.

SHANGHAI, CHINA, November 14, 2022Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as Bioperfectus), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems,includingNucleic AcidSSNP-2000B,SSNP-3000A,SSNP-9600A,SMPE-960andExtraction Rapid Kit (Magnetic Bead Method). Bioperfectus Nucleic Acid Extraction Rapid Kit can be applied to a variety of sample types such as nasopharyngeal swab, pharyngeal swab, nasal swab, serum, plasma, urine, cervical swab, urethral swab. The purified nucleic acid can be used in downstream molecular biology experiments, including in-vitro testing. As a one-stop supplier, Bioperfectus also provides different throughputs of nucleic acid extraction systems such as SSNP and SMPE series, which allows the customers to have more flexible choices based on their sample throughput. Bioperfectus nucleic acid extraction solutions, including systems and kits, could satisfy the requirements of nucleic acid purification with multiple specimen types in automatic or manual ways. The approval allows Bioperfectus to expand access to nucleic acid extraction solutions in Malaysia and offer more diagnostics solutions for local laboratories. Click here to download MDA Registration Certification. About Bioperfectus Since its founding in 2010, Bioperfectus(SSE:688399) has been dedicated to providing holistic molecular diagnostic solutions specializing in emerging infectious diseases for generations and generations to come. We are leading the change by offering Real-Time PCR Kits, Nucleic Acid Extraction Systems, Automation Solutions, and Rapid Tests to laboratories, hospitals, institutions, and CDCs across the globe. Bioperfectus products have been distributed to more than 100 countries around the world. As one of the leading global IVD suppliers, Bioperfectus is committed to delivering excellent services and products that meet the highest international quality and safety standards. Our global presence enables us to build close relationships with our clients and leverage our expertise to support them worldwide. To "Embrace the world with health" has always been our mission. But that's not where our mission ends. We are getting what we have learned, researched, and prepared for the subsequent emergency calls from infectious diseases and saving people's lives. For more information, please follow us on LinkedIn or visit www.bioperfectus.com. Media Contact:marketing_global@bioperfectus.com

SHANGHAI, CHINA, September 30, 2022Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as Bioperfectus) applied for the clinical evaluation in XYZ Laboratory (XYZ Laboratory 2009 Ranch Rd. 620 N, STE 325, Austin, TX 78732, USA), a CAP accredited CLIA certified high complexity clinical molecular diagnostic laboratory to perform and report the Bioperfectus Monkeypox Virus (MPXV) Fast Real Time PCR Kit. In this study, we have performed a systematic evaluation of the analytical performance of the Bioperfectus Monkeypox Virus (MPXV) Fast Real Time PCR Kit. The assay is highly sensitive, fast, and easy to use. This study has established the specification of the assay when used in a CLIA certificated high complexity Laboratory: The clinical performance: 97.43% PPA* and 100% NPA*. *Positive percentage of agreement (PPA), Negative percentage of agreement (NPA) With real clinical samples tested, the validation result shows solid evidence that Bioperfecuts Monkeypox Virus (MPXV) Fast Real Time PCR Kit has high clinically qualified sensitivity and specificity to fulfill the virus detection and diagnosis requirement in PCR laboratories. Positive control and negative control were validated, allowing the interpretation of the results. (If you need more information about the evaluation report, please email us at info@bioperfectus.com) Since the Monkeypox outbreak in several originally non-endemic countries in May, it has affected over 100 countries with almost 80,000 confirmed cases and 38 deaths. With rapid response, reliable and trustworthy performance, Bioperfectus has always stuck to the first line of fighting against infectious disease outbreaks as a manufacturer specializing in molecular diagnosis for over a decade. So far, over 200,000 test kits have been delivered to over 100 countries around the globe. Bioperfectus Monkeypox Virus Diagnostic Solution has been validated, approved, and used to test and track the Monkeypox virus in several high and key-level public and private laboratories worldwide.